SCHEMBL7202871

SCHEMBL7202871

N[C@@H](CCS)C(=O)N[C@@H](CCS)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 1/20 0.43
FOLH1 Q04609 2/20 0.41
PTGS1 P23219 2/20 0.40
SLC7A11 Q9UPY5 1/20 0.40
GSTK1 Q9Y2Q3 1/20 0.39
NOD1 Q9Y239 1/20 0.38
ANPEP P15144 1/20 0.38
ENPEP Q07075 1/20 0.38
RIMKLA Q8IXN7 1/20 0.38
NAALAD2 Q9Y3Q0 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
ALOX15 P16050 1/20 0.38
NFKB1 P19838 1/20 0.38
PTGS2 P35354 1/20 0.38
THPO P40225 1/20 0.38
RECQL P46063 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7202874 1.00 ACE (0.43) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL29402233 0.96 ACE (0.41) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL29402083 0.96 ACE (0.41) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL29405310 0.96 ACE (0.41) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL30437433 0.96 ACE (0.41) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL30438134 0.96 ACE (0.41) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL929324 0.91 PTGS1 (0.48) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL21134741 0.91 ACE (0.55) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL16770231 0.91 ACE (0.55) ACEFOLH1PTGS1SLC7A11GSTK1
SCHEMBL30625400 0.91 PTGS1 (0.48) ACEFOLH1PTGS1SLC7A11GSTK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS PROTAGONIST THERAPEUTICS, INC. 2025-09-04 US disclosed
CN-115436540-B Method and kit for simultaneously measuring folic acid and homocysteine content in blood 汤臣倍健股份有限公司 2024-11-26 CN disclosed
US-11565240-B2 Mixed mode affinity chromatography carrier FUJIFILM CORPORATION (JP) 2023-01-31 US disclosed
CN-115436540-A Method and kit for simultaneously determining contents of folic acid and homocysteine in blood 汤臣倍健股份有限公司 2022-12-06 CN disclosed
US-6589751-B2 Antibody specific for homocystamide adducts, such as those formed by dehydrating homocysteine to homocysteine thiolactone and reaction this with a carrier such as low density lipoprotein (LDL) to form homocystamide-LDL adduct MCW RESEARCH FOUNDATION 2003-07-08 US disclosed
US-20020015968-A1 IMMUNOLOGICAL DETECTION OF THE HOMOCYSTAMIDE ADDUCT AND A THIOLACTONE IMMUNOASSAY FOR ENDOGENEOUS HOMOCYSTEINE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250277012-A1 CONJUGATED HEPCIDIN MIMETICS HAMP, VIP, HDGF ACE 3865/4885FOLH1 66/4885PTGS1 657/4885
US-11565240-B2 Mixed mode affinity chromatography carrier FCGR2A, FCGR3B, FCGR1A ACE 4311/4885FOLH1 368/4885PTGS1 4651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.